Present and future therapy for hepatitis C virus

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 5, 2006, Pages 781-793

  Cornberg, Markus ^a   Deterding, Katja ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute; Antiviral therapy; Chronic hepatitis C; HCV infection; Hepatitis C; Interferon a; Polymerase inhibitor; Procease inhibitor; Ribavicin; Therapeutic vaccine

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALBUMIN ALPHA INTERFERON; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CILUPREVIR; CONSENSUS INTERFERON; CPG 10101; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS C VACCINE; INTERFERON; ISATORIBINE; MERIMEPODIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; R 1626; RECOMBINANT ALPHA INTERFERON; RIBAMIDINE; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCH 503034; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; VALOPICITABINE; VX 950;

APATHY; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SYNTHESIS; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRRITABILITY; KIDNEY FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; META ANALYSIS; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; SUICIDE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; FORECASTING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; PREDICTIVE VALUE OF TESTS; VIRAL HEPATITIS VACCINES;

EID: 33845398404     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.5.781     Document Type: Review

References (101)

1. Shepard CW, Finelli L, Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5(9), 558-567 (2005).
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902), 359-362 (1989).
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 36(5 Suppl. 1), S21-S29 (2002).
4. Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 345(1), 41-52 (2001).
5. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 26(3 Suppl. 1), S15-S20 (1997).
6. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J. Hepatol. 31(Suppl. 1), 39-42 (1999).
7. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 9(4), 331-338 (2003).
8. Cornberg M, Wedemeyer H, Manns MP, Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr. Gastroenterol. Rep. 4(1), 23-30 (2002).
9. Cornberg M, Manns MP. New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C. Ann. Hepatol. 4(3), 144-150 (2005).
10. Frank C, Mohamed MK, Strickland GT et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355(9207), 887-891 (2000).
11. Buchbinder SP, Katz MH, Hessol NA, Liu J, O'Malley PM, Alter MJ. Hepatitis C virus infection in sexually active homosexual men. J. Infect. 29(3), 263-269 (1994).
12. + T cells in chronic hepatitis C virus infection. J. Immunol. 169(6), 3447-3458 (2002).
13. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5(3), 215-229 (2005).
14. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436(7053), 961-966 (2005).
15. Di Bisceglie AM, Frey S, Gorse GJ et al. A Phase I safety and immunogenicity trial of a novel E1E2/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults. Hepatology 42(4), 750A (2005).
16. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 36(5 Suppl. 1), S65-S73 (2002).
17. 2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig. Dis. Sci. 41(12 Suppl.), S81-S85 (1996).
18. 2b. N. Engl. J. Med. 345(20), 1452-1457 (2001).
19. 2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J. Hepatol. 42(3), 329-333 (2005).
20. Broers B, Helbling B, Francois A et al. Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J. Hepatol. 42(3), 323-328 (2005).
21. 2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 43(2), 250-256 (2006).
22. Kamal SM, Ismail A, Graham CS et al. Pegylated interferon-α therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 39(6), 1721-1731 (2004).
23. Hofer H, Watkins-Riedel T, Janata O et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 37(1), 60-64 (2003).
24. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125(1), 80-88 (2003).
25. Fleig WE, Krummenerl P, Lesske J et al. [Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents - results of an evidence-based consensus conference of the German Society for Alimentary Metabolic Disorders and incooperation with the Hepatitis Competence Network]. Z. Gastroenterol. 42(8), 703-704 (2004).
26. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N. Engl. J. Med. 345(3), 215-217 (2001).
27. Manns MP, Meyer S, Wedemeyer H. The German network of excellence for viral hepatitis (Hep-Net). Hepatology 38(3), 543-544 (2003).
28. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J. Med. Virol. 73(3), 387-391 (2004).
29. + T cell response in mediating HCV clearance and evolution. Hepatology 43(3), 563-572 (2006).
30. 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001).
31. 2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
32. 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346-355 (2004).
33. 2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38(3), 645-652 (2003).
34. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37(3), 600-609 (2003).
35. 2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 44(1), 97-103 (2006).
36. 2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129(2), 522-527 (2005).
37. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40(6), 1260-1265 (2004).
38. 2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 of 3. N. Engl. J. Med. 352(25), 2609-2617 (2005).
39. 2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. J. Hepatol. 44(2), S271 (2006).
40. 2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 40(6), 993-999 (2004).
41. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123(4), 1061-1069 (2002).
42. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 36(5 Suppl. 1), S237-S244 (2002).
43. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with α-interferon therapy for chronic viral hepatitis. J. Hepatol. 21(2), 241-243 (1994).
44. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon α. N. Engl. J. Med. 344(13), 961-966 (2001).
45. Schaefer M, Schwaiger M, Garkisch AS et al. Prevention of interferon-α associated depression in psychiatric risk patients with chronic hepatitis C. J. Hepatol. 42(6), 793-798 (2005).
46. Afdhal NH, Dieterich DT, Pockros PJ et al. Epoetin α maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 126(5), 1302-1311 (2004).
47. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35(5), 1002-1009 (2002).
48. Perelson AS, Ribeiro RM. Mutagenic effects of ribavirin in vivo. J. Hepatol. 43(4), 553-555 (2005).
49. Sintchak MD, Nimmesgern E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 47(2-3), 163-184 (2000).
50. 2a in interferon-nonresponder patients with chronic hepatitis C. J. Hepatol. 37(6), 843-847 (2002).
51. Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr. Opin. Investig. Drugs 3(5), 680-683 (2002).
52. 2a. J. Hepatol. 42, 39 (2005).
53. 2b in therapy-naive patients infected with HCV: Phase 3 results. J. Hepatol. 44(2), S273 (2006).
54. 2b for treatment of chronic hepatitis C. J. Hepatol. 28(3), 382-389 (1998).
55. Van Thiel DH, Faruki H, Friedlander L et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 42(6), 907-912 (1995).
56. Soza A, Everhart JE, Ghany MG et al. Neutropenia during combination therapy of interferon-α and ribavirin for chronic hepatitis C. Hepatology 36(5), 1273-1279 (2002).
57. 2a plus ribavirin. Gastroenterology 130(4), 1086-1097 (2006).
58. 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122(5), 1303-1313 (2002).
59. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon-α and γ inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 21(4), 1003-1010 (1995).
60. Curry M, Cardenas A, Afdhal NH. Effect of maintenance PEG-Intron therapy on portal hypertension and its complications: results from the COPILOT study. J. Hepatol. 42(Suppl. 2), 40 (2005).
61. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J. Pharmacol. Exp. Ther. 308(3), 1191-1196 (2004).
62. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39(2), 273-278 (2004).
63. Schiff ER, Pockros P, Shiffman ML et al. 66 Oral IDN-6556: An anti-apoptotic caspase inhibitor, lowers aminotransferases in HCV patients. J. Hepatol. 40(Suppl. 1), 24 (2004).
64. Hinrichsen H, Benhamou Y, Wedemeyer H et al. Short-term antiviral efficacy of BILN, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127(5), 1347-1355 (2004).
65. Reesink HW, Zeuzem S, Weegink CJ et al. Final results of a Phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 42(4), 234A-235A (2005).
66. 2a. J. Hepatol. 44(2), S272 (2006).
67. Zeuzem S, Sarrazin C, Rouzier R et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-α). Hepatology 42(4), 233A-234A (2005).
68. Zeuzem S, Sarrazin C, Wagner F et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders: Phase IB results. Hepatology 42(4), 276A-277A (2005).
69. O'Brien C, Godofsky E, Rodriguez-Torres M et al. Randomized trial of valopicitabine (NM283), alone or with peg-interferon, vs retreatment with PEG-interferon plus ribavirin (pegifn/RBV) in hepatitis C patients with previous non-response to pegifn/RBV: first interim results. Hepatology 42(4), 234A (2005).
70. Dieterich D, Lawitz E, Nguyen T et al. Early clearance of HCV RNA with Valopicitabine (NM283) plus PEG-interferon in treatment-naive patients with HCV-1 infection: first results from a Phase IIb trial. J. Hepatol. 44(2), S271 (2006).
71. Roberts S, Cooksley G, Shaw D et al. Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients. J. Hepatol. 44(2), S269 (2006).
72. Sarrazin C, Kieffer T, Bartels D et al. Characterization of viral variants in the HCV NS3 protease domain of genotype 1 patients that are selected during 14 days of dosing with VX-950. Hepatology 42(4), 751A (2005).
73. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424), 110-113 (1999).
74. Reiser M, Hinrichsen H, Benhamou Y et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41(4), 832-835 (2005).
75. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11(7), 791-796 (2005).
76. Kempf DJ, Chen H-J, Yeung CM et al. Pharmacokinetic boosting of VX-950, an inhibitor of HCV protease, by co-dosing with ritonavir. J. Hepatol. 44(2), S4 (2006).
77. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-α species, consensus interferon. J. Interferon Cytokine Res. 16(7), 489-499 (1996).
78. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon-Con1 with natural recombinant interferons-α: antiviral, antiproliferative, and natural killer-inducing activities. J. Interferon Res. 12(1), 55-59 (1992).
79. Tong MJ, Reddy KR, Lee WM et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 26(3), 747-754 (1997).
80. 2b and ribavirin in the treatment of chronic hepatitis C. Dig. Dis. Sci. 50(4), 727-732 (2005).
81. Kaiser S, Hass HG, Gregor M. Successful retreatment of interferon/ ribavirin nonresponders with daily dosing of consensus interferon. J. Hepatol. 42(Suppl. 2), 207-208 (2005).
82. Cornberg M, Hadem J, Herrmann E et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J. Hepatol. 44(2), 291-301 (2006).
83. 2b combined with ribavirin in genotype 1 chronic hepatitis C infection. J. Hepatol. 44(2), S270 (2006).
84. Bechet A, Verrijk R, Humphries J, Vennecker E, de Leede L. Pharmacokinetics, safety and biomarkers in man after administration of Locteron, a once every two-weeks controlled release formulation of interferon-α. J. Hepatol. 44(2), S210 (2006).
85. McHutchinson JG, Ghalib R, Lawitz E et al. Early viral response to CPG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. J. Hepatol. 44(2), S269 (2006).
86. Horsmans Y, Brenard R, Starkel P et al. Tolerability and immunogenicity of HCV E1 therapeutic vaccination in patients with chronic hepatitis C on interferon plus ribavirin. J. Hepatol. 42, 207 (2005).
87. Nevens F, Roskams T, Van Vlierberghe H et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38(5), 1289-1296 (2003).
88. Nevens F, Roskams T, Van Vlierberghe H et al. Improvement in liver histology after 3 years of E1 therapeutic vaccination in 23 patients with chronic hepatitis C. Hepatology 40(4), 250A-251A (2004).
89. Manns MP, Berg T, Wedemeyer H et al. Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non-responder patients. Hepatology 40(4), 251A (2004).
90. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 12(8), 1192-1204 (2006).
91. Boker KH, Dalley G, Bahr MJ et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 25(1), 203-210 (1997).
92. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J. Hepatol. 42(4), 448-456 (2005).
93. Forns X, Garcia-Retortillo M, Serrano T et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J. Hepatol. 39(3), 389-396 (2003)
94. Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev. Gastroenterol. Disord. 4(Suppl. 1), S31-S38 (2004).
95. Terrault NA. Prophylactic and pre-emptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl. 9(11), S95-S100 (2003).
96. 2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 41(2), 289-298 (2005).
97. 2b and ribavirin combination. J. Hepatol. 40(4), 669-674 (2004).
98. 2b and ribavirin: an open-label series. Transplantation 77(2), 190-194 (2004).
99. 2b and ribavirin therapy. Transplantation 78(9), 1303-1307 (2004).
100. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of PEGinterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment. Pharmacol. Ther. 20(9), 931-938 (2004).
101. 2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 54(6), 858-866 (2005).